| 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 口服制剂(元) | 35,012,021.00 | 19,842,658.92 | 61,037,725.56 | 33,576,843.78 |
| 原料药(元) | 4,217,471.85 | 2,197,714.77 | 8,797,641.28 | 5,577,599.77 |
| 注射剂(元) | 217,122,842.41 | 93,288,450.99 | 156,418,992.12 | 68,730,734.04 |
| 营业成本(元) | ||||
| 口服制剂(元) | 15,397,373.17 | 7,602,312.20 | 17,754,780.73 | 7,913,762.33 |
| 原料药(元) | 2,366,757.21 | 1,327,032.92 | 5,045,257.61 | 2,364,473.01 |
| 注射剂(元) | 92,486,785.64 | 42,759,138.13 | 75,634,087.71 | 25,122,552.70 |
| 毛利(元) | ||||
| 口服制剂(元) | 19,614,647.83 | 12,240,346.72 | 43,282,944.83 | 25,663,081.45 |
| 原料药(元) | 1,850,714.64 | 870,681.85 | 3,752,383.67 | 3,213,126.76 |
| 注射剂(元) | 124,636,056.77 | 50,529,312.86 | 80,784,904.41 | 43,608,181.34 |
| 毛利率(%) | ||||
| 口服制剂(%) | 56.02 | 61.69 | 70.91 | 76.43 |
| 原料药(%) | 43.88 | 39.62 | 42.65 | 57.61 |
| 注射剂(%) | 57.40 | 54.16 | 51.65 | 63.45 |
| 收入构成(%) | ||||
| 口服制剂(%) | 13.66 | 17.21 | 26.98 | 31.12 |
| 原料药(%) | 1.65 | 1.91 | 3.89 | 5.17 |
| 注射剂(%) | 84.70 | 80.89 | 69.13 | 63.71 |
| 毛利构成(%) | ||||
| 口服制剂(%) | 13.43 | 19.23 | 33.86 | 35.40 |
| 原料药(%) | 1.27 | 1.37 | 2.94 | 4.43 |
| 注射剂(%) | 85.31 | 79.40 | 63.20 | 60.16 |